Background: Since the detection of circulating tumor cells (CTCs) which express HER2 is an adverse prognostic factor in early breast cancer patients, we investigated the effect of trastuzumab on patients' clinical outcome.
introduction
The detection of disseminated (DTCs) and circulating (CTCs) tumor cells in patients with early stage breast cancer [1] [2] [3] is a well recognized independent prognostic factor associated with increased risk of disease recurrence and disease-related death [3] [4] [5] [6] [7] . Recent studies have demonstrated that adjuvant chemotherapy [8] [9] [10] or tamoxifen [11] cannot eliminate DTCs/CTCs probably because of their non-proliferating and/or dormant state [12] . Moreover, the proliferative potential and the in vitro growth characteristics of DTCs [13] as well as their persistence after adjuvant chemotherapy and/or tamoxifen are associated with unfavorable prognosis [8] [9] [10] [11] .
DTCs and CTCs may express the HER2 oncoprotein in 60-70% early stage patients with breast cancer [14] [15] [16] [17] , and often present HER2 gene amplification and aneusomy [18, 19] . Interestingly, HER2 expression on DTCs/CTCs is independent of its expression on primary tumor cells [16] [17] [18] [19] [20] [21] [22] . A shift of breast cancer patients' CTCs from HER2(-) to HER2(+) status [23] has been attributed to acquired HER2 gene amplification during cancer progression [24] . The detection of HER2 oncoprotein on DTCs and CTCs has been associated with an increased risk of death [16] [17] [18] [19] [20] [21] [22] and decreased disease-free interval [22] ; moreover, HER2 mRNA-positive CTCs have independent prognostic value for worse disease-free and overall survival [25, 26] .
The humanized monoclonal antibody trastuzumab (Herceptin), which is directed against the extracellular domain of the HER2 protein, has been shown to inhibit the in vitro and in vivo growth of malignant cells and enhance the antitumor efficacy of some chemotherapeutic agents [27] . In addition, trastuzumab is part of the standard care of patients with HER2-positive tumors in the adjuvant and metastatic settings.
We have reported that trastuzumab can effectively eliminate CK19 mRNA-positive CTCs and DTCs in women with breast cancer irrespectively of the HER2 status of primary tumor cells [19] . Based on this observation and the fact that the detection of CK + /HER2+ DTCs/CTCs is an adverse prognostic factor for patients' outcome, we investigated whether "secondary adjuvant" administration of trastuzumab could decrease the incidence of relapses in patients with chemotherapy-resistant CTCs; the study was conducted in women with early stage HER2-negative breast cancer who were at high risk of relapse because they had detectable CK19 mRNA-positive CTCs before and after the completion of adjuvant chemotherapy [5, 10] . Our results demonstrate that treatment with "secondary adjuvant" trastuzumab resulted in a significantly reduced probability of disease relapse and increased disease-free interval compared to patients receiving only standard treatment.
patients and methods patients
Women with histologically confirmed operable (stage I-III) breast adenocarcinoma with detectable CK19 mRNA-positive CTCs both before and after the administration of adjuvant chemotherapy and radiotherapy (when indicated), treated in our Department were eligible [10] . Additional inclusion criteria were: age >18 years, surgery (lumpectomy or mastectomy) for the primary tumor, performance status 0-2 (WHO), adequate bone marrow, renal and liver function, normal left ventricular ejection fraction (LVEF), absence of a second primary tumor (except of in situ cervical cancer or a squamous skin cancer) and, absence of any clinical or radiological evidence of distant metastasis. Since the study was initiated in 2003 and before the approval of trastuzumab administration in the adjuvant setting (2005), initially no limitation concerning the HER2 status of the primary tumor was applied; from 2005, an amendment excluded patients with HER2-positive tumors from the study since trastuzumab was for them standard adjuvant treatment. HER2 status was determined by immunohistochemistry (IHC; 3 + ) or/and FISH (for 1-2 + by IHC). Patients received standard adjuvant systemic treatment (CMF or FEC regimens or sequential combination of epirubicin/cyclophosphamide followed by docetaxel) as well as radiation therapy according to the international guidelines. Furthermore, postmenopausal patients with hormone receptor-positive tumors received either tamoxifen or aromatase inhibitors whereas pre-menopausal patients were treated with LH/RH analogues and tamoxifen.
CK19 mRNA testing
All patients were routinely assessed for the presence of CK19 mRNApositive CTCs at the time of initial staging of their disease and before any systemic treatment; in addition, patients were sequentially assessed for the presence of CK19 mRNA-positive CTCs after the completion of adjuvant chemotherapy and radiotherapy as well as every 3 months thereafter. Patients' treatment was independent of their CK19 mRNA status. Peripheral blood in EDTA was obtained: i) before and after the completion of adjuvant chemotherapy/radiotherapy; ii) in patients randomized to the trastuzumab arm after the 6 th administration of trastuzumab and iii) in those enrolled in the observation arm, 4 months after the completion of adjuvant chemotherapy/radiotherapy (a period corresponding to that of "secondary adjuvant" trastuzumab administration). All blood samples were obtained in the middle of vein puncture, RNA was extracted from peripheral blood mononuclear cells (PBMCs) within 6 hours and CK19 mRNA-positive cells were detected by real-time PCR as described [28] . According to the analytical detection limit of our assay, values ≥0.6 MCF-7 equivalents/ 5 µg of total RNA were considered as a positive result. Using the above cut-off, only two (2.2%) out of 89 female healthy donors were positive whereas none of 11 women with benign breast disease had positive blood samples.
Detection of CK + /HER2+ cells
Cytospins (250.000 PBMCs/slide) were prepared by cyto-centrifugation, air dried and stored at -80 0 C. CK-positive cells in PBMCs' cytospins were assessed by immunofluorescence using the mouse A45-B/B3 (detecting CK8, CK18 and CK19) (Micromet Munich, Germany) antibody as previously reported [29, 30] . The Meng's et al [13] cyto-morphological criteria (i.e. high nuclear/cytoplasmic ratio, larger cells than white blood cells etc) were used in order to characterize a CK-positive cell as a CTC.
Cytospins were also double stained with anti-CD45 (Santa Cruz, Santa Cruz, CA, USA) and A45-B/B3 antibodies in order to exclude possible ectopic expression of cytokeratins on hematopoietic cells [28, 29] . For HER2 detection on CTCs, slides were stained for cytokeratin along with the corresponding secondary (FITC) Alexa Fluor 488 (Invitrogen, Carlsbad, CA, USA) and then, the anti-HER2 anti-rabbit (Cell Signalling Technology, Boston, MA, USA) and the corresponding Alexa Fluor 555 anti-rabbit secondary antibodies (Invitrogen) were added. SKBR3 tumor cells were used as positive control; negative controls were the same cells stained with the secondary IgG isotype antibody (Invitrogen) without adding the primary antibody. Finally, Dapi-antifade reagent (Invitrogen) was added to each sample. Slides were evaluated using a confocal laser scanning microscope (Leica Lasertechnik, Heidelberg, Germany) and images were analyzed with the respective software. Specific staining was easy to distinguish because of the differential intracellular distribution [31] .
treatment
Patients received either trastuzumab (Herceptin, Roche, Basel, Switzerland; a loading dose of 8mg/kg as a 30-minutes IV infusion followed by 5 administrations of 6mg/kg IV, every 3 weeks) or only observation. No other treatment was allowed except of the adjuvant hormone treatment for patients with hormone receptor-positive tumors. All patients were followed every 3 months for the first 2 years, every 6 months for the subsequent 3 years and every year thereafter with clinical, biochemical, tumor markers (CEA and CA 15.3) and imaging studies (chest x-rays, abdominal ultrasound or additional tests if clinically indicated) in order to exclude distant metastases. Trastuzumab-related cardiac toxicity was monitored by assessment of the LVEF before and after the administration of trastuzumab. Patients gave their informed consent to participate in the study which was approved by the Ethics and Scientific Committees of our Institution.
statistical analysis
In this pilot, randomized phase II trial, patients were centrally randomized, using a computer-derived random allocation sequence; stratification factors were the menopausal, axillary lymph node and hormone receptor status.
The primary end-point of the study was disease-free survival (DFS) rate atBased on previous data from our laboratory it was assumed that the DFS rate at 3 years of patients with CK-19 mRNA-positive cells both before and after adjuvant chemotherapy receiving standard treatment would be 60%; it was estimated that 32 evaluable patients should be enrolled on each arm to show a 50% increase of DFS rate for the trastuzumab arm with a power of 80% at a statistical significant level of 0.05. Cox proportional hazards model for time to event data was used for the univariate analysis along with Log-Rank test for the Kaplan-Meier curves. The Wilcoxon test was used to investigate differences in related samples. Analysis also included contingency tables, t or Mann-Whitney tests and Chi-square tests. Significant interaction between effectiveness of trastuzumab administration and other clinicopathological variables was assessed by using heterogeneity tests and forest plots were made. The statistical significant level was set at 0.05 (2-sided).
results patients and treatment
From February 2003-December 2008, 378 patients (310 and 68 with HER2-negative and -positive early breast cancer, respectively) were treated. 148 (39%) patients with detectable CK19 mRNA-positive CTCs before any adjuvant systemic treatment represent the cohort of patients screened for this trial. Of those, 100 (26%) patients also had detectable CK19 mRNA-positive CTCs after the completion of adjuvant chemotherapy and radiotherapy and were eligible for study enrollment; three patients were excluded since they did not meet the inclusion criteria (two had a second primary tumor and one severe heart failure) whereas two other patients refused to participate in the trial. Ninety-five patients were randomized to the trastuzumab (n = 46) or observation (n = 49) arm. Among them, nine (20%) and 10 (20%) patients, randomized in the trastuzumab and the observation arm, respectively before 2005, had a HER2-positive primary tumor and were excluded from the final analysis. One additional patient, randomized to receive trastuzumab, withdrew her consent before treatment administration and, therefore, 36 and 39 patients were evaluable in the trastuzumab and the observation arm, respectively, and were included in the final analysis (CONSORT diagram; Figure 1 ). The clinicopathological characteristics of the enrolled patients as well as the administered treatment [adjuvant chemotherapy, radiotherapy and hormone treatment] were well balanced ( Table 1 ). All patients received the six scheduled trastuzumab cycles uneventfully without significant cardiac or other toxicities.
detection of CK19 mRNA-positive cells
At the end of trastuzumab therapy, 23 of 32 (72%; 4 patients had no CTCs' enumeration) women turned CK19 mRNAnegative whereas only seven of 27 (26%; 12 patients had no CTCs' enumeration) women of the observation arm had undetectable CK19 mRNA-positive CTCs 4 months (corresponding to the period of trastuzumab administration) Figure 1 . CONSORT diagram of the study (Table 2 ; p = 0.085). In addition, the median number of CK19 mRNA-positive CTCs at the end of trastuzumab administration was significantly lower than that of patients enrolled in the observation arm (Table 2 ; p <0.001).
HER2 expression on CK+ CTCs
Double staining experiments for the detection of CK + /HER2+ CTCs were performed in 57 patients for whom adequate material was available (in 18 patients, cytospins were inappropriate for analysis due to the intense background in the negative controls). CK + /HER2+ CTCs could be detected in 51 (90%) of the evaluable patients. In nine patients all the recognized CTCs were CK + /HER2+ whereas in 42 (82%) patients the existence of a subpopulation of CK + /HER2-CTCs could also be detected. The median number of CK + /HER2+ CTCs was 2.0 (range, 1-37) in the trastuzumab arm and 2.0 (range, 1-47) in the observation arm.
disease recurrence and survival
After a median follow up period of 67.2 months (range, 6.83-92.97), 19 (25%) patients presented a distant relapse. All but four of these relapses occurred in patients enrolled in the observation arm ( p = 0.008; Table 3 ). There was no difference in terms of clinical relapses between the two arms according to menopausal ( p = 0.66), hormone receptor ( p= 0.114) status or patients with N0 ( p = 0.456) or <3 involved axillary lymph nodes ( p = 0.212) (Table 3) . Conversely, the incidence of relapses was significantly higher in the observation than in the trastuzumab arm in post-menopausal patients ( p = 0.006), those with hormone receptor-negative tumors ( p = 0.042) and patients with >3 involved axillary lymph nodes ( p = 0.004) (Table 3) . Ηowever, the interaction test could demonstrate heterogeneity only between the axillary lymph nodes' groups ( Figure 2 ). Although the median DFS has not yet been reached, it was significantly longer in patients treated with trastuzumab ( p = 0.008; Figure 3 ). Six (8.0%) patients died because of disease progression during the follow up period; all but two deaths occurred in the group of patients randomized to the observation arm ( p = 0.676). There was no significant difference in terms of overall survival between the two arms (Supplemantary Figure 1 ; p = 0.506); there was no significant interaction between the different groups for trastuzumab effect on overall survival or Disease Free Survival.
univariate and multivariate analysis
Univariate analysis including menopausal status, tumor size, number of infiltrated axillary lymph nodes, histopathological grade, ER, PR status and trastuzumab administration revealed that only randomization to the observation arm was significantly (p = 0.014) associated with a decreased DFS ( Table 4 ). Since only one parameter emerged as significant in the univariate analysis no further multivariate analysis was performed. Moreover, none of the examined parameters showed any significant association with overall survival (Table 4) .
discussion
To the best of our knowledge this is the first randomized clinical study investigating the effect of a "secondary" adjuvant therapy targeting chemotherapy-resistant CTCs in patients with early breast cancer. The results demonstrate that targeting chemo-resistant CTCs with trastuzumab significantly reduced the risk of relapse and prolonged the DFS. Moreover, the administration of trastuzumab resulted in a significantly decreased number of patients with detectable CTCs by eliminating these cells.
The development of clinical recurrences in patients with operable breast cancer is due to the migration of tumor cells from the primary tumor to distant organs even before the surgical excision of the primary tumor. Using immunocytochemical or molecular techniques [1] [2] [3] , epithelial cells, with genetic heterogeneity [32] , loss of heterozygosity [33] or/and chromosomal aberrations [34] ,can be detected in the bone marrow and the peripheral blood of patients with early breast cancer. The detection of these cells is associated with an unfavorable outcome [4, 7] . Moreover, the detection of CTCs after adjuvant treatment (chemotherapy or tamoxifen), is an independent adverse prognostic factor [8, [10] [11] [12] ; since these cells are resistant to chemotherapy and tamoxifen, it is important to define whether biological treatments could effectively target them.
HER2/neu expression is involved in cell proliferation [35] and is associated with poor clinical outcome [36] . Since HER2 is expressed on DTCs or/and CTCs in breast cancer patients [12, [14] [15] [16] [17] it was considered as a suitable target for the development of a "secondary adjuvant" biologic therapy. We have demonstrated that the administration of 3-4 trastuzumab infusions in patients with detectable CK19 mRNA-positive CTCs or/and DTCs could specifically eliminate these cells in 67% of patients [19] . In the current study, we chose to administer 6 cycles of trastuzumab based on the observation from our "proof-of-principle" study (19) that in some patients CK19 mRNA-positive cells reappeared 1-3 months after the discontinuation of trastuzumab. This finding suggests that despite the decrease of CTCs' number in trastuzumab-treated 
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patients under the detection limit of the assay, residual populations of CTCs lead to early relapse of CK19 mRNApositive CTCs [18] . Similarly, Barok et al [37] using a xenograft model, demonstrated that trastuzumab significantly decreased the number of DTCs and CTCs even in cases with trastuzumab-resistant primary tumor. The high efficacy of trastuzumab on the elimination of CK19 mRNA-positive CTCs should be attributed to the fact that almost 90% of the evaluated patients had HER2-expressing CTCs. Therefore, we can hypothesize that the trastuzumab-induced elimination of CTCs might have resulted in the decreased incidence of disease recurrences in patients treated with trastuzumab; in addition, the administration of trastuzumab was associated with a significantly prolonged DFS. These results were obtained in a rather high risk group of patients since all of them had detectable CK19 mRNA-positive CTCs after adjuvant chemotherapy, which has been shown to confer the worst prognosis in terms of clinical relapses and disease-related deaths [10] . In addition, although subgroup analysis indicated that the trastuzumab effect was mainly observed in post-menopausal patients with hormone receptornegative tumors and with >3 involved lymph nodes, the interaction test demonstrated heterogeneity only with lymph nodes; therefore, larger studies are required to elucidate these observations.
The described beneficial effect of trastuzumab was observed in patients with HER2-negative primary tumors. It is well known that HER2 expression on DTCs or/and CTCs is not correlated with the HER2 status of the primary tumor [15, [17] [18] [19] 21, 22] and occult tumor cells can acquire HER2 gene amplification over time [24, 25] . Our findings may explain the intriguing results from a subset analysis of the NSABP B-31 trial in women with early breast cancer who derived benefit from adjuvant trastuzumab although they had HER2-negative tumors by central testing [38] . This observation suggests that the benefit of trastuzumab might not be confined exclusively to patients with HER2-positive primary tumors. Moreover, the reported data raise the question whether the molecular characteristics of CTCs/DTCs in patients with solid tumors could be more predictive of the efficacy of targeted treatments.
Undoubtfully, the current study has some important limitations: i) Since the control group did not receive placebo we cannot totally exclude a "non-specific" treatment effect of trastuzumab although we have previously shown that nonspecific immunoglobulin failed to eliminate CTCs [19] . ii) The small number of enrolled patients limits the statistical power of our study and therefore, our results should be considered as 'proof of principle". iii) Nineteen HER2-positive patients enrolled before 2005 were excluded from the final analysis in order to avoid a bias due to HER2 status heterogeneity. iv) Finally, the study did not include monitoring of the CK (+)/HER2(+) CTCs, during trastuzumab treatment.
In conclusion, our results provide preliminary evidence that targeting chemotherapy-resistant CTCs may be clinically meaningful since "secondary" adjuvant trastuzumab, in patients with early breast cancer and detectable CK19 mRNApositive cells, reduced the probability of disease recurrence. A larger, multicenter, prospective randomized clinical trial is required to confirm these findings. Moreover, the molecular characterization of CTCs during treatment and at the time of relapse could improve our understanding on the role of CTCs in the metastatic process. 
